Cephalon, Inc. (Nasdaq: CEPH) announced the pooled analysis of two pivotal randomized, placebo-controlled clinical trials showing that AMRIX® (cyclobenzaprine hydrochloride extended-release capsules), a new once-daily extended-release skeletal muscle relaxant, was superior to placebo. AMRIX had similar efficacy to cyclobenzaprine immediate-release (CIR) taken three times a day in alleviating acute muscle spasm associated with lower back and neck pain.

More: continued here

This entry was posted on Tuesday, February 19th, 2008 at 8:02 am and is filed under Pain / Anesthetics. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.